Vimarsana
Biggest News Aggregation in the World

H Lundbeck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from H Lundbeck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In H Lundbeck Today - Breaking & Trending Today

Lu-AG22515 by H. Lundbeck for Neuromyelitis Optica (Devic's Syndrome): Likelihood of Approval - Vimarsana News

Lu-AG22515 by H. Lundbeck for Neuromyelitis Optica (Devic's Syndrome): Likelihood of Approval

Published: November 4, 2023

Lu-AG22515 is under clinical development by H. Lundbeck and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome).

Source: pharmaceutical-technology.com
Related Topics:
South KoreaH LundbeckCompany ProfileCompany ProfilesLundbeck FoundationNeuromyelitis Optica
ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment - Vimarsana News

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Published: November 2, 2023

SEATTLE, November 02, 2023--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced the addition of multiple industry veterans to its leadership team to support its growth.

Source: yahoo.com
Related Topics:
San DiegoUnited StatesKeck Graduate InstituteUniversity Of Southern CaliforniaBaiteng ZhaoKevin HamblyXiao ShangLori KunkelErin LavelleLos AngelesYale UniversityUniversity Of CaliforniaVp Corporate Development Strategy At Eliem TherapeuticsDivision Of Hematology OncologySociety For Immunotherapy Of CancerMerrill Lynch CoKeck Graduate Institute Of Applied Life SciencesAlder Biopharmaceuticals IncWashington UniversityScientific Advisory BoardTae HanNurix TherapeuticsLoxo OncologyHarpoon TherapeuticsBaxter Healthcare
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck - Vimarsana News

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

Published: May 8, 2023

/PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesZheng LiThomas Mikkel MortensenTarek SamadGlobal Head Of Research At LundbeckTherapeutics IncH LundbeckGlobal HeadRelations LeadNeuro3 Therapeutics
FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Illinois - Vimarsana News

FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Illinois

Published: April 28, 2023

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 27, 2023--

Source: wsiltv.com
Related Topics:
United StatesNordrhein WestfalenJohn KrausJohan LuthmanStatesjeffrey GilbertStatesdyana LescohierStatesrobert MurphyOtsuka America Pharmaceutical IncAmerican Psychiatric AssociationOtsuka Pharmaceutical Development Commercialization IncCo LtdOtsuka Pharmaceutical Co LtdOtsuka Holdings Co LtdDrug AdministrationH LundbeckOtsuka Pharmaceutical Company LtdPsychopharmacology InstituteWorld Health OrganizationNational Institute Of Mental HealthRoserm Mental HealthNational Pregnancy Registry For Atypical AntipsychoticsCorporate CommunicationsAmerica PharmaceuticalNew Drug ApplicationImportant Safety Information
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia | Illinois - Vimarsana News

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia | Illinois

Published: April 17, 2023

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 16, 2023--

Source: wsiltv.com
Related Topics:
United StatesJohn KrausClin NeurosciStatesrobert MurphyStatesdyana LescohierOtsuka Holdings Co LtdLundbeck PharmaceuticalsOtsuka Pharmaceutical Company LtdCentral Nervous System Drugs Advisory CommitteeOtsuka America Pharmaceutical IncInternational Psychogeriatric AssociationOtsuka Pharmaceutical Development Commercialization IncMeeting Of The Psychopharmacologic Drugs Advisory CommitteeHealth CanadaCorporate CommunicationsOtsuka Pharmaceutical Co LtdH LundbeckDrug AdministrationPharmaceutical DevelopmentJoint MeetingPsychopharmacologic Drugs Advisory CommitteeNew Drug ApplicationDrug User Fee ActCohen Mansfield Agitation InventoryTotal Score